Learning objectives
Upon completion of this activity, participants should be able to:

• Identify disease targets appropriate for ASCVD risk reducing genetic treatments
• Compare preclinical assessment strategies for candidate gene editing therapeutic modalities
• Recognize challenges faced by novel one time gene editing therapies in the transition to clinical trials.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.

"*Credit (if available) is announced on the Group Home page. All sessions on the Group Home page. All sessions are reviewed individually and credit is pulled for any that does not meet the criteria."